Liu H S, Perry H D, Refojo M F
Ophthalmologica. 1980;181(1):41-6. doi: 10.1159/000309023.
Various dosages of the anticancer agent 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine, BCNU) were administered to 28 normal rabbit eyes. Single injections and series of injections were given to determine the tolerance and toxicity levels of this drug when injected directly into the vitreous cavity, the anterior chamber, or the subtenon-retrobulbar space. During a follow-up period of 3 weeks to 4 months, no significant ocular changes were noted following a single injection of BCNU into the vitreous (0.002--0.50 mg) or anterior chamber (0.001--0.250 mg), or 10 daily subtenon-retrobulbar injections (0.5--1.0 mg each). When the daily dosage was increased to 1.5--2.0 mg, corneal damage with stromal infiltration, edema, and vascularization were found after the course of the 10 subtenon-retrobulbar injections in 3 of 6 test animals.
将不同剂量的抗癌药物1,3-双(2-氯乙基)-1-亚硝基脲(卡莫司汀,BCNU)注射到28只正常兔眼中。通过单次注射和系列注射来确定将该药物直接注射到玻璃体腔、前房或球后Tenon囊下间隙时的耐受性和毒性水平。在3周4个月的随访期内,向玻璃体(0.002-0.50mg)或前房(0.001-0.250mg)单次注射BCNU,或进行10次球后Tenon囊下每日注射(每次0.5-1.0mg)后,未观察到明显的眼部变化。当每日剂量增加到1.5-2.0mg时,6只试验动物中有3只在进行10次球后Tenon囊下注射后出现角膜损伤,伴有基质浸润、水肿和血管化。